Navigation Links
Hebrew University researchers neutralize tumor growth in embryonic stem cell therapy
Date:5/6/2009

Jerusalem, May 5, 2009 Researchers at the Hebrew University of Jerusalem have discovered a method to potentially eliminate the tumor-risk factor in utilizing human embryonic stem cells. Their work paves the way for further progress in the promising field of stem cell therapy.

Human embryonic stem cells are theoretically capable of differentiation to all cells of the mature human body (and are hence defined as "pluripotent"). This ability, along with the ability to remain undifferentiated indefinitely in culture, make regenerative medicine using human embryonic stem cells a potentially unprecedented tool for the treatment of various diseases, including diabetes, Parkinson's disease and heart failure.

A major drawback to the use of stem cells, however, remains the demonstrated tendency of such cells to grow into a specific kind of tumor, called teratoma, when they are implanted in laboratory experiments into mice. It is assumed that this tumorigenic feature will be manifested upon transplantation to human patients as well. The development of tumors from embryonic stem cells is especially puzzling given that these cells start out as completely normal cells.

A team of researchers at the Stem Cell Unit in the Department of Genetics at the Silberman Institute of Life Sciences at the Hebrew University has been working on various approaches to deal with this problem.

In their latest project, the researchers analyzed the genetic basis of tumor formation from human embryonic stem cells and identified a key gene that is involved in this unique tumorigenicity. This gene, called survivin, is expressed in most cancers and in early stage embryos, but it is almost completely absent from mature normal tissues.

The survivin gene is especially highly expressed in undifferentiated human embryonic stem cells and in their derived tumors. By neutralizing the activity of survivin in the undifferentiated cells as well as in the tumors, the researchers were able to initiate programmed cell death (apoptosis) in those cells.

This inhibition of this gene just before or after transplantation of the cells could minimize the chances of tumor formation, but the researchers caution that a combination of strategies may be needed to address the major safety concerns regarding tumor formation by human embryonic stem cells.


'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert  

Related biology news :

1. Antioxidant to retard wrinkles discovered by Hebrew University researcher
2. Hebrew SeniorLife researchers search for aging, osteoporosis genes
3. Five young Hebrew University scientists win first competitive EU grants
4. Electronic structure of DNA revealed for 1st time by Hebrew University and collaborating researchers
5. Hebrew University study opening new route for combating viruses
6. Hebrew University develops novel approach for treating mitochondrial disorders
7. Scent on demand: Hebrew University scientists enhance the scent of flowers
8. Hebrew University scientists reveal mechanism that triggers differentiation of embryo cells
9. Hebrew University professors work leads to FDA approval for product
10. A study by the MUHC and McGill University opens a new door to understanding cancer
11. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hebrew University researchers neutralize tumor growth in embryonic stem cell therapy
(Date:3/20/2017)... 2017 PMD Healthcare announces the release of ... Management System (WMS), a remote, real-time lung health monitoring ... Healthcare is a Medical Device, Digital Health, and Chronic ... creating innovative solutions that empower people to improve their ... PMD developed the first ever personal spirometer, Spiro PD, ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 ... and 23andMe , the leading personal genetics company, ... Zipongo can now provide customers with personalized nutrition plans ... and biometrics, but also genetic markers impacting how their ... Zipongo,s personalized food decision support platform uses biometrics such ...
Breaking Biology News(10 mins):
(Date:4/21/2017)... ... April 21, 2017 , ... ... to nourishing a range of emerging technology-based businesses, recently earned a $77,518 grant ... location. , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit ...
(Date:4/20/2017)... 20, 2017  Eli Lilly and Company (NYSE: ... galcanezumab for the prevention of migraine at the American ... place April 22-28, 2017, in Boston ... at AAN, including safety and patient outcomes data for ... a reduction in monthly migraine headache days among patients ...
(Date:4/20/2017)... ... April 20, 2017 , ... NetDimensions appoints Bill Mastin, a ... over 20 years of experience in the learning technologies industry, Mastin joins NetDimensions from ... Learning Technologies Group plc (LTG). At LEO, Mastin served as SVP of the North ...
(Date:4/20/2017)... ... 20, 2017 , ... Parallel6™ , the leader in mClinical™ technologies for ... were named one of the 2017 Top 10 eClinical Trial Management Solution Providers ... industry. , “We take pride in honoring Parallel6 as one of the top 10 ...
Breaking Biology Technology: